Get the Stockscreener App
5.09
4.32%
-0.23
After Hours:
5.09
Aldeyra Therapeutics Inc stock is traded at $5.09, with a volume of 1.21M.
It is down -4.32% in the last 24 hours and up +34.30% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$5.32
Open:
$5.3
24h Volume:
1.21M
Relative Volume:
1.08
Market Cap:
$304.87M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-6.7867
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
-5.04%
1M Performance:
+34.30%
6M Performance:
-1.74%
1Y Performance:
+29.19%
1-Day Range:
$5.02
$5.32
1-Week Range:
$5.02
$5.62
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.09 | 318.64M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Why did ALDX's EPS remain stagnant in recent quarters? - AInvest
How does Aldeyra Therapeutics Inc. generate profit in a changing economyMarket Forecast Target Finder For 2025 - jammulinksnews.com
How Aldeyra Therapeutics Inc. stock performs during market volatilityFundamental Growth Stock Analysis Shows Strength - metal.it
What makes Aldeyra Therapeutics Inc. stock attractive to long term investorsAnalyst Grade Signals - metal.it
What is the risk reward ratio of investing in Aldeyra Therapeutics Inc. stockCapitalize on strategic market trends - jammulinksnews.com
Why is Aldeyra Therapeutics Inc. stock attracting strong analyst attentionDiscover stocks with explosive upside potential - jammulinksnews.com
What are Aldeyra Therapeutics Inc. company’s key revenue driversUnlock high-yield investment opportunities - jammulinksnews.com
How volatile is Aldeyra Therapeutics Inc. stock compared to the marketInvest smarter with expert stock recommendations - jammulinksnews.com
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA - Ophthalmology Times
Is Aldeyra Therapeutics Inc. a good long term investmentExplosive earning power - PrintWeekIndia
Aldeyra Therapeutics Receives Orphan Designation from the Europe - GuruFocus
What drives Aldeyra Therapeutics Inc. stock priceFree Risk Assessment Services - PrintWeekIndia
What analysts say about Aldeyra Therapeutics Inc. stockExceptional gains - Autocar Professional
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies - Ophthalmology Times Europe
EMA grants orphan designation for Aldeyra’s eye treatment By Investing.com - Investing.com India
EMA grants orphan designation for Aldeyra’s eye treatment - Investing.com
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa - The Globe and Mail
Published on: 2025-07-23 18:29:07 - Autocar Professional
Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN
FDA accepts Aldeyra's resubmitted reproxalap NDA - Eyes On Eyecare
FDA accepts for review Aldeyra Therapeutics’ resubmitted new drug application for reproxalap - Optometry Times
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Aldeyra Therapeutics Announces FDA Acceptance for Review of Repr - GuruFocus
Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Lelezard
FDA Accepts Aldeyra’s Reproxalap Application for Review - TipRanks
FDA Reviews Aldeyra's (ALDX) Reproxalap for Dry Eye Disease | AL - GuruFocus
FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug By Investing.com - Investing.com Nigeria
FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug - Investing.com
FDA Reviews Breakthrough Dry Eye Drug: Aldeyra's Reproxalap Could Transform Treatment Landscape - Stock Titan
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
why aldeyra therapeutics inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
What makes Aldeyra Therapeutics Inc. stock price move sharplyCapital Safe Smart Trades - Newser
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
10.28%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):